Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients
J Crosnier, P Jungers, AM Couroucé, A Laplanche… - The Lancet, 1981 - Elsevier
A vaccine against hepatitis B surface antigen (Institut Pasteur Production) was assessed in
138 haemodialysis patients in a placebo-controlled randomised double-blind trial. In an
interim analysis, hepatitis B infections were observed in 21% of the vaccine group and 45%
of the placebo group (p< 0· 02). 2 of the infections in the vaccine group and 12 of the
infections in the placebo group occurred after the third injection. 60% of the vaccine
recipients had an immune response. 4 months after the first injection the mean titre of anti …
138 haemodialysis patients in a placebo-controlled randomised double-blind trial. In an
interim analysis, hepatitis B infections were observed in 21% of the vaccine group and 45%
of the placebo group (p< 0· 02). 2 of the infections in the vaccine group and 12 of the
infections in the placebo group occurred after the third injection. 60% of the vaccine
recipients had an immune response. 4 months after the first injection the mean titre of anti …
Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff
J Crosnier, P Jungers, AM Couroucé, A Laplanche… - The Lancet, 1981 - Elsevier
A vaccine against hepatitis B surface antigen (Institut Pasteur Production) was assessed in
staff members from forty-eight French haemodialysis units where the risk of hepatitis B was
high. Of 318 subjects who completed the protocol, 164 received three monthly injections of
vaccine and 154 received corresponding injections of placebo. Hepatitis B infection was
observed in 3· 6% of the vaccine group and 12· 3% of the placebo group (p< 0· 005). The 6
infections in the vaccine group all arose within 63 days from the first injections, whereas the …
staff members from forty-eight French haemodialysis units where the risk of hepatitis B was
high. Of 318 subjects who completed the protocol, 164 received three monthly injections of
vaccine and 154 received corresponding injections of placebo. Hepatitis B infection was
observed in 3· 6% of the vaccine group and 12· 3% of the placebo group (p< 0· 005). The 6
infections in the vaccine group all arose within 63 days from the first injections, whereas the …
